Evolving Cardioprotective Strategies in Cardio-Oncology: A Narrative Review.

IF 3.3 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Cardiology Reports Pub Date : 2025-09-09 DOI:10.1007/s11886-025-02283-y

Elena Wadden, Sanjay Chandrasekhar, Timothy Jordan, Andrea Diaz, Marta Alhama-Belotto, Efstathia Andrikopoulou, Douglas Leedy, Alexi Vasbinder, Richard K Cheng

{"title":"Evolving Cardioprotective Strategies in Cardio-Oncology: A Narrative Review.","authors":"Elena Wadden, Sanjay Chandrasekhar, Timothy Jordan, Andrea Diaz, Marta Alhama-Belotto, Efstathia Andrikopoulou, Douglas Leedy, Alexi Vasbinder, Richard K Cheng","doi":"10.1007/s11886-025-02283-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: Patients living with cancer are at risk for significant potential cardiovascular complications as a direct result of cancer treatment or due to underlying comorbid cardiovascular disease. This article reviews the methods of risk stratification as well as pharmacologic and nonpharmacologic approaches to cardioprotection in cardio-oncology.Recent findings: Several cancer-specific risk stratification tools have incorporated variables such as age, sex, cancer subtype, traditional cardiovascular risk factors and cancer treatment-related parameters to assess cardiovascular specific risk prior to cancer therapy. Cardioprotective strategies, namely neurohormonal blockade and statins, have yielded mixed results in patients with cancer. Non-pharmacologic strategies, including exercise and dietary interventions, have shown potentially promising results in observational and randomized studies. Ultimately, the optimal cardioprotective strategy should be personalized based on each patient's unique risk profile and clinical context. Further research is needed to better define the role of cardioprotection across different cancer subtypes and cardiovascular risk groups, with an emphasis on refining individualized prevention and treatment strategies.","PeriodicalId":10829,"journal":{"name":"Current Cardiology Reports","volume":"27 1","pages":"131"},"PeriodicalIF":3.3000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cardiology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11886-025-02283-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Patients living with cancer are at risk for significant potential cardiovascular complications as a direct result of cancer treatment or due to underlying comorbid cardiovascular disease. This article reviews the methods of risk stratification as well as pharmacologic and nonpharmacologic approaches to cardioprotection in cardio-oncology.

Recent findings: Several cancer-specific risk stratification tools have incorporated variables such as age, sex, cancer subtype, traditional cardiovascular risk factors and cancer treatment-related parameters to assess cardiovascular specific risk prior to cancer therapy. Cardioprotective strategies, namely neurohormonal blockade and statins, have yielded mixed results in patients with cancer. Non-pharmacologic strategies, including exercise and dietary interventions, have shown potentially promising results in observational and randomized studies. Ultimately, the optimal cardioprotective strategy should be personalized based on each patient's unique risk profile and clinical context. Further research is needed to better define the role of cardioprotection across different cancer subtypes and cardiovascular risk groups, with an emphasis on refining individualized prevention and treatment strategies.

查看原文本刊更多论文

心脏肿瘤学中不断发展的心脏保护策略：叙述性回顾。

回顾的目的：癌症患者由于癌症治疗或潜在的共病心血管疾病而面临显著潜在心血管并发症的风险。本文综述了心血管肿瘤学中危险分层的方法以及药物和非药物方法对心脏保护的影响。最近的发现：一些癌症特异性风险分层工具纳入了年龄、性别、癌症亚型、传统心血管危险因素和癌症治疗相关参数等变量，以评估癌症治疗前的心血管特异性风险。心脏保护策略，即神经激素阻断和他汀类药物，在癌症患者中产生了不同的结果。非药物策略，包括运动和饮食干预，在观察性和随机研究中显示出潜在的有希望的结果。最终，最佳的心脏保护策略应该根据每个患者独特的风险概况和临床情况进行个性化。需要进一步的研究来更好地定义心脏保护在不同癌症亚型和心血管风险人群中的作用，重点是完善个性化的预防和治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Cardiology Reports CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

6.20

自引率

2.70%

发文量

209

期刊介绍： The aim of this journal is to provide timely perspectives from experts on current advances in cardiovascular medicine. We also seek to provide reviews that highlight the most important recently published papers selected from the wealth of available cardiovascular literature. We accomplish this aim by appointing key authorities in major subject areas across the discipline. Section editors select topics to be reviewed by leading experts who emphasize recent developments and highlight important papers published over the past year. An Editorial Board of internationally diverse members suggests topics of special interest to their country/region and ensures that topics are current and include emerging research. We also provide commentaries from well-known figures in the field.